Xiangyang No.1 People's Hospital
🇨🇳China
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
Phase 1
Not yet recruiting
- Conditions
- NK CellB-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
- Interventions
- Combination Product: autologous NK cell
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Xiangyang No.1 People's Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT05909098
- Locations
- 🇨🇳
EC of Xiangyang No.1 People's Hospital Hubei University of Medicine, Hubei, Xiangyang, China
© Copyright 2025. All Rights Reserved by MedPath